Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy

World Journal of Urology

Volumn 32, Issue 3, 2014, Pages 631-642

  Kim, Dae Y ^a   Karam, Jose A ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Kidney cancer; Metastasectomy; Renal cell carcinoma; Targeted therapy

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ADJUVANT THERAPY; CARCINOMA, RENAL CELL; HUMAN; IMMUNOTHERAPY; KIDNEY NEOPLASMS; METASTASIS RESECTION; NEPHRECTOMY; PATHOLOGY; PROCEDURES; PROGNOSIS; SECONDARY;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; METASTASECTOMY; NEOADJUVANT THERAPY; NEPHRECTOMY; PROGNOSIS;

EID: 84901343666     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1293-6     Document Type: Article

References (73)

1. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR (2008) Renal cell cancer stage migration: analysis of the national cancer data base. Cancer 113(1): 78-83. doi: 10. 1002/cncr. 23518.
2. Chen DY, Uzzo RG (2009) Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw: JNCCN 7(6): 635-642 quiz 643.
3. Russo P (2011) The role of surgery in the management of early-stage renal cancer. Hematol Oncol Clin North Am 25(4): 737-752. doi: 10. 1016/j. hoc. 2011. 04. 009.
4. Flanigan RC (2004) Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 10(18 Pt 2): 6335S-6341S. doi: 10. 1158/1078-0432. CCR-sup-040026.
5. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286): 966-970.
6. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76(5): 824-832.
7. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316(15): 889-897. doi: 10. 1056/nejm198704093161501.
8. Vogelzang NJ, Lipton A, Figlin RA (1993) Subcutaneous interleukin-2 plus interferon α-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol: Off J Am Soc Clin Oncol 11(9): 1809-1816.
9. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer: the Cochrane database of systematic reviews (1): CD001425. doi: 10. 1002/14651858. CD001425. pub2.
10. Kim B, Louie AC (1992) Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 127(11): 1343-1349 Chicago Ill: 1960.
11. Krishnamurthi V, Novick AC, Bukowski RM (1998) Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51(6): 933-937.
12. Breau RH, Blute ML (2010) Surgery for renal cell carcinoma metastases. Curr Opin Urol 20(5): 375-381. doi: 10. 1097/MOU. 0b013e32833c7ada.
13. Russo P, O'Brien MF (2008) Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 35(4): 679-686. doi: 10. 1016/j. ucl. 2008. 07. 009.
14. Staehler M (2011) The role of metastasectomy in metastatic renal cell carcinoma. Nat Rev Urol 8(4): 180-181. doi: 10. 1038/nrurol. 2011. 30.
15. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 24(1): 16-24. doi: 10. 1200/jco. 2005. 02. 2574.
16. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 24(16): 2505-2512. doi: 10. 1200/jco. 2005. 03. 6723.
17. Rini BI, Sosman JA, Motzer RJ (2005) Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96(3): 286-290. doi: 10. 1111/j. 1464-410X. 2005. 05616. x.
18. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ (2011) Targeted therapy for advanced renal cell cancer (RCC): a cochrane systematic review of published randomised trials. BJU Int 108(10): 1556-1563. doi: 10. 1111/j. 1464-410X. 2011. 10629. x.
19. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB (1997) Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158(5): 1691-1695.
20. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 17(8): 2530-2540.
21. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 23(4): 832-841. doi: 10. 1200/JCO. 2005. 05. 179.
22. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 20(1): 289-296.
23. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P (2008) Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 180(3): 873-878. doi: 10. 1016/j. juro. 2008. 05. 006 discussion 878.
24. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A (2003) Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98(12): 2566-2575. doi: 10. 1002/cncr. 11851.
25. Lara PN, Jr., Tangen CM, Conlon SJ, Flanigan RC, Crawford ED, Southwest Oncology Group Trial S (2009) Predictors of survival of advanced renal cell carcinoma: long-term results from southwest oncology group trial S8949. J Urol 181(2): 512-516. doi: 10. 1016/j. juro. 2008. 10. 021 discussion 516-517.
26. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 16(6): 2261-2266.
27. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48(1): 77-81. doi: 10. 1016/j. eururo. 2005. 03. 004 discussion 81-72.
28. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13): 2873-2882. doi: 10. 1002/cncr. 25836.
29. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol: Off J Am Soc Clin Oncol 27(34): 5794-5799. doi: 10. 1200/JCO. 2008. 21. 4809.
30. Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W, Takahashi M, Terachi T, Ozono S, Naito S, Tomita Y (2013) Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82(4): 846-851. doi: 10. 1016/j. urology. 2013. 06. 035.
31. Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I (2006) Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5(3): 232-234. doi: 10. 3816/CGC. 2006. n. 042.
32. Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC (2009) Surgical resection of renal cell carcinoma after targeted therapy. J Urol 182(3): 881-886. doi: 10. 1016/j. juro. 2009. 05. 014.
33. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM (2011) Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2): 439-444. doi: 10. 1016/j. juro. 2010. 09. 086.
34. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4): 973-980. doi: 10. 1093/annonc/mdr362.
35. Weiss L, Harlos JP, Torhorst J, Gunthard B, Hartveit F, Svendsen E, Huang WL, Grundmann E, Eder M, Zwicknagl M et al (1988) Metastatic patterns of renal carcinoma: an analysis of 687 necropsies. J Cancer Res Clin Oncol 114(6): 605-612.
36. Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung. J Urol 42: 269-276.
37. Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI (1992) Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 54(1): 33-38.
38. Murthy SC, Kim K, Rice TW, Rajeswaran J, Bukowski R, DeCamp MM, Blackstone EH (2005) Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 79(3): 996-1003. doi: 10. 1016/j. athoracsur. 2004. 08. 034.
39. Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF, Pairolero PC (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57(2): 339-344.
40. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74(5): 1653-1657.
41. Assouad J, Petkova B, Berna P, Dujon A, Foucault C, Riquet M (2007) Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 84(4): 1114-1120. doi: 10. 1016/j. athoracsur. 2007. 04. 118.
42. Assouad J, Riquet M, Berna P, Danel C (2007) Intrapulmonary lymph node metastasis and renal cell carcinoma. Eur J Cardiothorac Surg 31(1): 132-134. doi: 10. 1016/j. ejcts. 2006. 10. 025.
43. Reinke RT, Higgins CB, Niwayama G, Harris RH, Friedman PJ (1976) Bilateral pulmonary hilar lymphadenopathy: an unusual manifestation of metastatic renal cell carcinoma. Radiology 121(1): 49-53. doi: 10. 1148/121. 1. 49.
44. Winter H, Meimarakis G, Angele MK, Hummel M, Staehler M, Hoffmann RT, Hatz RA, Lohe F (2010) Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. J Urol 184(5): 1888-1894. doi: 10. 1016/j. juro. 2010. 06. 096.
45. Kawashima A, Nakayama M, Oka D, Sato M, Hatano K, Mukai M, Nagahara A, Nakai Y, Takayama H, Inoue M, Shiono H, Nishimura K, Okumura M, Nonomura N (2011) Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience. Int J Clin Oncol 16(6): 660-665. doi: 10. 1007/s10147-011-0244-0.
46. Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Ruttinger D, Lohe F, Preissler G, Hatz RA, Winter H (2011) Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg 202(2): 158-167. doi: 10. 1016/j. amjsurg. 2010. 06. 029.
47. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK (2013) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. doi: 10. 1016/j. eururo. 2013. 08. 012.
48. Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL (2010) Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(4): 1185-1192. doi: 10. 1016/j. ijrobp. 2009. 03. 062.
49. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schoffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4): 794-800. doi: 10. 1093/annonc/mdq554.
50. Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ (2008) Sorafenib for metastatic renal cancer: the princess Margaret experience. Am J Clin Oncol 31(2): 182-187. doi: 10. 1097/COC. 0b013e3181574084.
51. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18): 4256-4265. doi: 10. 1002/cncr. 25219.
52. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22(2): 295-300. doi: 10. 1093/annonc/mdq342.
53. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8): 1794-1801. doi: 10. 2106/JBJS. F. 00603.
54. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, Sylvester R, Group EGTC (2009) Radical nephrectomy with and without lymph-node dissection: final results of European organization for research and treatment of cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55(1): 28-34. doi: 10. 1016/j. eururo. 2008. 09. 052.
55. Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, van Poppel H (2011) Lymph node dissection in renal cell carcinoma. Eur Urol 60(6): 1212-1220. doi: 10. 1016/j. eururo. 2011. 09. 003.
56. Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML (2008) Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol 180(1): 99-103. doi: 10. 1016/j. juro. 2008. 03. 025.
57. Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D (2006) Outcome following hepatic resection of metastatic renal tumors: the Paul brousse hospital experience. HPB 8(2): 100-105. doi: 10. 1080/13651820500496266.
58. Hatzaras I, Gleisner AL, Pulitano C, Sandroussi C, Hirose K, Hyder O, Wolfgang CL, Aldrighetti L, Crawford M, Choti MA, Pawlik TM (2012) A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB 14(8): 532-538. doi: 10. 1111/j. 1477-2574. 2012. 00495. x.
59. Ruys AT, Tanis PJ, Iris ND, van Duijvendijk P, Verhoef C, Porte RJ, van Gulik TM (2011) Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 18(7): 1932-1938. doi: 10. 1245/s10434-010-1526-x.
60. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98(2): 342-349. doi: 10. 3171/jns. 2003. 98. 2. 0342.
61. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS (2008) Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 113(7): 1641-1648. doi: 10. 1002/cncr. 23769.
62. Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53(2): 376-381. doi: 10. 1016/j. eururo. 2007. 08. 053.
63. Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP (2007) Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 27(6C): 4255-4257.
64. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21): 4958-4965. doi: 10. 1002/cncr. 26138.
65. Soffietti R, Trevisan E, Ruda R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6): 679-686. doi: 10. 1097/CCO. 0b013e3283571a1c.
66. Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL (2012) The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 116(5): 978-983. doi: 10. 3171/2012. 2. JNS111353.
67. Tanis PJ, van der Gaag NA, Busch OR, van Gulik TM, Gouma DJ (2009) Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 96(6): 579-592. doi: 10. 1002/bjs. 6606.
68. Chung AY, Tran TB, Brumund KT, Weisman RA, Bouvet M (2012) Metastases to the thyroid: a review of the literature from the last decade. Thyroid 22(3): 258-268. doi: 10. 1089/thy. 2010. 0154.
69. Hegerova L, Griebeler ML, Reynolds JP, Henry MR, Gharib H (2013) Metastasis to the thyroid gland: report of a large series from the mayo clinic. Am J Clin Oncol. doi: 10. 1097/COC. 0b013e31829d1d09.
70. Antonelli A, Arrighi N, Corti S, Legramanti S, Zanotelli T, Cozzoli A, Cunico SC, Simeone C (2012) Surgical treatment of atypical metastasis from renal cell carcinoma (RCC). BJU Int 110(11 Pt B): E559-E563. doi: 10. 1111/j. 1464-410X. 2012. 11271. x.
71. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E, Group EGW (2011) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6): Vi25-vi30. doi: 10. 1093/annonc/mdr372.
72. Ismaili N (2011) Treatment of colorectal liver metastases. World J Surg Oncol 9: 154. doi: 10. 1186/1477-7819-9-154.
73. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E (2009) Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4): 456-460. doi: 10. 1111/j. 1464-410X. 2009. 08490. x.